Welcome to our dedicated page for MINIMED GROUP news (Ticker: MMED), a resource for investors and traders seeking the latest updates and insights on MINIMED GROUP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MINIMED GROUP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MINIMED GROUP's position in the market.
MiniMed (Nasdaq: MMED) reported Q1 FY27 net sales of $843 million, up 16.6% as reported and 15.8% organic, including an estimated 4–6% benefit from an extra week in the 52–53 week fiscal calendar. Excluding this benefit, MiniMed achieved low double-digit organic growth.
International net sales rose to $603 million, up 18.1% reported and 16.9% organic, supported by Simplera capacity expansion and the Instinct sensor. U.S. net sales reached $240 million, up 13.1%, with U.S. New Pumps Sold growing over 20% year over year and worldwide NPS of ~34,000 (+7.7%). The worldwide CGM attachment rate increased to 69%, about 100 bps higher quarter over quarter.
MiniMed advanced its pipeline with a U.S. FDA submission for the MiniMed Fit patch pump, CE Mark for MiniMed Flex with a November EU launch expected, completion of enrollment in the Vivera fully-closed loop U.S. pivotal trial, and IDE approval for a next‑gen extended wear sensor. For FY27, MiniMed now expects organic revenue growth of ~10.5%, including a 1.0–1.5% extra-week benefit, up from ~10%, and reaffirms an adjusted EBITDA margin outlook of ~16%.
MiniMed (Nasdaq: MMED) announced that its management will join fireside chats at two investor conferences. The company will participate in the 21st Annual Wells Fargo Healthcare Conference on September 8, 2026, at 3:00 p.m. EDT / 12:00 p.m. PDT, featuring CEO Que Dallara. MiniMed will also attend the Bank of America Global Healthcare Conference 2026 on September 23, 2026, at 10:55 a.m. BST / 5:55 a.m. EDT / 2:55 a.m. PDT with CEO Que Dallara and CFO Chad Spooner. According to MiniMed, live webcasts and replays will be available on its investor relations website.
MiniMed (Nasdaq: MMED) announced that its MiniMed Flex™ automated insulin delivery system is now commercially shipping in the U.S. with the Instinct sensor, made by Abbott. For the first time, users can combine MiniMed’s smallest and only app-controlled insulin pump with what the company calls the world’s smallest, patient-applied sensor, offering up to 15 days of wear.
Powered by SmartGuard™ technology, MiniMed Flex™ automatically adjusts insulin around the clock and uses Meal Detection™ to help when meal boluses are occasionally missed. The pump holds up to 300 units of insulin, works with the Extended™ infusion set for up to seven days’ wear, and is FDA cleared for people with type 1 diabetes aged 7+ and adults with insulin-requiring type 2 diabetes.
MiniMed (Nasdaq: MMED) announced that Medicare and Medicare Advantage beneficiaries in the U.S. now have access to the MiniMed Flex™ insulin pump system with its latest sensor portfolio. This expansion makes MiniMed’s smallest and only app-controlled pump available to more people living with diabetes.
MiniMed Flex™ is about half the size of previous MiniMed pumps, roughly the size of two stacked insulin vials, yet holds 300 units of insulin. Powered by the same SmartGuard™ technology used in the MiniMed™ 780G system, it automatically adjusts insulin delivery every five minutes. According to MiniMed, real-world data in Medicare users of MiniMed™ 780G showed glycemic outcomes exceeding American Diabetes Association targets. In the U.S., MiniMed Flex™ is available with the Simplera Sync™ sensor and is expected to be available with Abbott’s Instinct sensor later this summer.
MiniMed (Nasdaq: MMED) announced it expects to report fiscal year 2027 first quarter financial results on Tuesday, September 1, 2026, covering the quarter ended July 31, 2026. A summary news release is expected around 3:45 a.m. PDT, followed by a webcast from 5:45 to 6:30 a.m. PDT, with replay and transcript available within 24 hours on the company’s investor website.
MiniMed (Nasdaq: MMED) appointed Alcon CEO David Endicott and Medtronic executive Linnea Burman to its Board of Directors, effective June 29, 2026, expanding the board from nine to 11 members.
Endicott joins the Compensation and Talent Committee, while Medtronic remains MiniMed's majority shareholder.
MiniMed (Nasdaq: MMED) launched in Europe the MiniMed™ 780G system integrated with the 15-day Instinct sensor and the MiniMed Go™ system integrated with the Instinct Go sensor, both made by Abbott.
CE-marked Instinct sensors expand MiniMed's portfolio, offering smaller, longer-wear CGM options with clinical data showing high Time in Range and strong overnight control.
MiniMed (Nasdaq: MMED) has commercially launched the MiniMed Flex™ system in the U.S., its first app-controlled and smallest insulin pump, paired initially with the Simplera Sync™ sensor.
The pump holds 300 units, uses the SmartGuard™ algorithm with Meal Detection™ technology, and real‑world data showed about 80% Time in Range with recommended settings. FDA clearance covers type 1 diabetes from age 7 and insulin‑requiring type 2 adults.
MiniMed (NASDAQ: MMED) announced an expanded agreement with Abbott to commercialize integrated dual glucose-ketone sensors designed to work exclusively with MiniMed smart dosing systems.
The same-size-as-Instinct sensors aim to enable early, real-time ketone detection to help prevent diabetic ketoacidosis (DKA). Abbott’s dual systems have CE Mark, are under FDA review, and are not yet cleared or available in the United States.
MiniMed (Nasdaq: MMED) reported strong Q4 and fiscal 2026 results and issued fiscal 2027 guidance.
Q4 net sales were $837 million, up 15.6% reported and 8.7% organic. Fiscal 2026 net sales reached a record $3.102 billion, up 14.2% reported and 8.0% organic, led by international growth and higher CGM attachment.
Fiscal 2027 guidance calls for ~10% organic revenue growth (including 1.0–1.5% from an extra week) and ~16% adjusted EBITDA margin. MiniMed advanced its pipeline with FDA clearances for MiniMed Flex and MiniMed Go, CE Marks for expanded MiniMed 780G indications, new launches, and an extended Abbott sensor partnership.